Research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a research report issued on Wednesday. The firm set a “hold” rating on the stock.
Can-Fite BioPharma Stock Down 1.9 %
Shares of CANF stock opened at $2.07 on Wednesday. The company has a market capitalization of $7.33 million, a price-to-earnings ratio of -1.16 and a beta of 1.58. Can-Fite BioPharma has a 12-month low of $1.81 and a 12-month high of $3.33. The firm has a fifty day moving average of $2.15 and a 200-day moving average of $2.10.
Can-Fite BioPharma (NYSE:CANF – Get Free Report) last announced its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.20 million. On average, equities analysts expect that Can-Fite BioPharma will post -0.03 EPS for the current year.
Institutional Investors Weigh In On Can-Fite BioPharma
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Recommended Stories
- Five stocks we like better than Can-Fite BioPharma
- Earnings Per Share Calculator: How to Calculate EPS
- Garmin Navigates to New Highs Driven By Wearables Trend
- What is the Dogs of the Dow Strategy? Overview and Examples
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- The Most Important Warren Buffett Stock for Investors: His Own
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.